NovaBay stock: buy or sell?
May 21st, 2019
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States.
Should I buy NovaBay stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with NovaBay stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NovaBay Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for NBY stock for the last 30 days.
NovaBay stock analysis
NovaBay Pharmaceuticals plunged a spooky -5.71% and closed at $0.33.
NovaBay ended today at $0.33 and plunged a spooky -5.71%.
NovaBay plummed a scary -15.38% this week. By mid April NBY boosted a dazzling 10.91% in just one week. For 3 weeks in a row, price slid and lost a -71.72%.
NovaBay stock price history
NovaBay IPO was on October 26th, 2007 at $105.00 per share1. Since then, NBY stock declined a -99.70%, with a yearly average of -9.10%.
1: Adjusted price after possible price splits or reverse-splits.
NovaBay stock historical price chart
NBY stock reached 52-week highs on June at $3.75, and all-time highs 2007-10-26 with a price of 106.25.
NovaBay stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NBY stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price target for NovaBay stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareNovaBay let down analysts on March when it reported an Earnings per Share (EPS) of $-0.09 when the market consensus was $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, NovaBay Pharmaceuticals annual turnover plummed a bloodcurdling -31.39% to $12.51 million USD from $18.23 marked in 2017. In the same way, its profit margin (compared to revenues) plummed to -52.33%, that is $-6.55 million.
|2013||$3.48 M||-||$-16.04 M-460.9%||-|
|2014||$1.05 M||-69.71%||$-15.19 M-1441.6%||-5.27%|
|2015||$4.38 M||315.65%||$-18.97 M-433.1%||24.87%|
|2016||$12 M||171.56%||$-13.15 M-110.5%||-30.69%|
|2017||$18 M||53.23%||$-7.40 M-40.6%||-43.71%|
|2018||$13 M||-31.39%||$-6.55 M-52.3%||-11.59%|
Quarterly financial resultsNovaBay Pharmaceuticals posted $3.63 million in sales for 2018-Q4, a 15.37% up compared to previous quarter. Reported quarter income marked $-1.27 M with a profit margin of -34.98%. Profit margin climbed a 13.97% compared to previous quarter when profit margin was -48.95%. When comparing sales to same quarter last year, NovaBay sales marked a spooky correction and plunged a -42.61%. Looking back to recent quarterly results, NovaBay Pharmaceuticals posted 2 positive quarters in a row.
|2017-Q1||$4 M||-||$-4.01 M-108.4%||-|
|2017-Q2||$4 M||11.35%||$-1.74 M-42.2%||-56.61%|
|2017-Q3||$4 M||-0.70%||$-2.45 M-59.8%||40.63%|
|2017-Q4||$6 M||54.39%||$0.79 M12.6%||-132.41%|
|2018-Q1||$3 M||-53.34%||$-2.15 M-73.0%||-371.12%|
|2018-Q2||$3 M||-5.19%||$-1.59 M-56.9%||-26.09%|
|2018-Q3||$3 M||12.46%||$-1.54 M-48.9%||-3.21%|
|2018-Q4||$4 M||15.37%||$-1.27 M-35.0%||-17.56%|
NovaBay ownershipWhen you are planning to buy a company, it's always worth to review its ownership structure.
NovaBay shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 25.87% of all shares.
In case of NovaBay stock, 4.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NBY stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$5.7 M||$367.4 B||$19.1 M||$477.5 M||$9.5 M|
|Total shares||17.2 M||2,660.0 M||76.5 M||80.9 M||12.0 M|
|Float shares||5.3 M||2,650.0 M||49.3 M||49.8 M||11.7 M|
|- Institutional holdings (%)||4.1%||69.2%||5.0%||30.2%||14.5%|
|- Insider holdings (%)||25.9%||0.1%||28.1%||33.0%||2.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$0.31 - $0.36|
|Average true range||$0.20|
|50d mov avg||$1.00|
|100d mov avg||$1.18|
|200d mov avg||$1.38|
NovaBay performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare NovaBay performance to , NanoViricides, SIGA Technologies, Sonoma Pharmaceuticals and Tetraphase Pharmaceuticals: